Johnson & Johnson (JNJ)
After hours:
| Previous close | 159.64 |
| Open | 159.75 |
| Bid | 160.75 x 800 |
| Ask | 160.90 x 800 |
| Day's range | 159.48 - 161.58 |
| 52-week range | 143.13 - 175.97 |
| Volume | |
| Avg. volume | 7,306,390 |
| Market cap | 386.699B |
| Beta (5Y monthly) | 0.52 |
| PE ratio (TTM) | 24.34 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.96 (3.09%) |
| Ex-dividend date | 27 Aug 2024 |
| 1y target est | N/A |
- PR Newswire
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
Johnson & Johnson (NYSE: JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of SPRAVATO® (esketamine) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression (TRD). Nearly 30 percent of the estimated 280 million people worldwide living with major depressive disorder (MDD) have TRD,1 which occurs when there is an inadequate response to two or more oral antidepressants dur
- Business Wire
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024
NEW BRUNSWICK, N.J., July 17, 2024--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2024 of $1.24 per share on the company’s common stock. The dividend is payable on September 10, 2024 to shareholders of record at the close of business on August 27, 2024. The ex-dividend date is August 27, 2024.
- Business Wire
Johnson & Johnson reports Q2 2024 results
NEW BRUNSWICK, N.J., July 17, 2024--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2024. "Johnson & Johnson's second quarter performance reflects our relentless focus on advancing the next wave of medical innovation and resulted in strong sales and adjusted operational earnings per share growth," said Joaquin Duato, Chairman and Chief Executive Officer. "With a robust pipeline, upcoming regulatory milestones for RYBREVANT and TREMFYA, the integration of Shockwave, and c
